FREE

Mendus - Recent clinical data highlight vididencel’s potential

Mendus recently presented positive data from two ongoing clinical studies, ADVANCE II and ALISON, at the EHA and ESMO conferences, respectively. While the Phase I ALISON trial, evaluating lead asset vididencel in ovarian cancer, met its primary endpoint of generating sufficient vaccine-induced responses (VIR), further analysis of ADVANCE II data (studying vididencel as a maintenance therapy in AML) confirmed the drug’s potential in generating a broader immune response through both T-cell and B-cell activation (vs selected T-cell action seen in antigen and neo-antigen-based approaches). This may be indicative of better clinical AML maintenance outcomes. We expect the next catalyst to be the Phase II CADENCE trial (patient enrolment to commence imminently), evaluating vididencel in combination with azacitidine (Onureg) in AML patients. Mendus is also planning a global registrational trial for vididencel, for which preparatory activities are expected to complete by H225.